{
    "ticker": "CLVSQ",
    "name": "Clovis Oncology, Inc.",
    "description": "Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing innovative cancer therapies. Founded in 2009, Clovis is dedicated to addressing the unmet medical needs of cancer patients by developing targeted therapies based on the genetic characteristics of tumors. The company's flagship product, Rubraca (rucaparib), is an oral medication approved for the treatment of certain types of ovarian cancer and has shown promise in treating other cancers with specific genetic mutations. Clovis is committed to advancing cancer care through rigorous clinical trials and has a pipeline of additional drug candidates aimed at various cancer indications. The company\u2019s approach combines a focus on precision medicine with a strong emphasis on patient-centric care, striving to improve the quality of life for patients battling cancer. With a mission to provide innovative treatment options and improve outcomes for patients, Clovis Oncology is at the forefront of the fight against cancer, collaborating with healthcare professionals and researchers to bring new therapies to market.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Boulder, Colorado, USA",
    "founded": "2009",
    "website": "https://www.clovisoncology.com",
    "ceo": "Patrick J. Mahaffy",
    "social_media": {
        "twitter": "https://twitter.com/ClovisOncology",
        "linkedin": "https://www.linkedin.com/company/clovis-oncology/"
    },
    "investor_relations": "https://investors.clovisoncology.com",
    "key_executives": [
        {
            "name": "Patrick J. Mahaffy",
            "position": "CEO"
        },
        {
            "name": "G. Alton McGarrity",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cancer Therapies",
            "products": [
                "Rubraca"
            ]
        }
    ],
    "seo": {
        "meta_title": "Clovis Oncology, Inc. | Innovative Cancer Therapies",
        "meta_description": "Clovis Oncology is focused on developing innovative cancer therapies to improve patient outcomes. Explore our mission, products, and advancements in cancer treatment.",
        "keywords": [
            "Clovis Oncology",
            "Cancer Therapies",
            "Rubraca",
            "Biopharmaceuticals",
            "Oncology"
        ]
    },
    "faq": [
        {
            "question": "What does Clovis Oncology specialize in?",
            "answer": "Clovis Oncology specializes in developing innovative cancer therapies."
        },
        {
            "question": "What is Rubraca?",
            "answer": "Rubraca is an oral medication developed by Clovis for the treatment of certain types of ovarian cancer."
        },
        {
            "question": "Where is Clovis Oncology headquartered?",
            "answer": "Clovis Oncology is headquartered in Boulder, Colorado, USA."
        },
        {
            "question": "When was Clovis Oncology founded?",
            "answer": "Clovis Oncology was founded in 2009."
        }
    ],
    "competitors": [
        "AMGN",
        "BMY",
        "JNJ",
        "REGN"
    ],
    "related_stocks": [
        "ABBV",
        "GILD",
        "VRTX",
        "MRNA"
    ]
}